Chronic activation of the innate immune system may underlie the metabolic syndrome
Palavras-chave:
Inflamação, Citocina, Diabetes não insulino dependente, Doença Cardiovascular, Obesidade, Síndrome XResumo
CONTEXTO: A síndrome metabólica se caracteriza por um agrupamento, em populações, de fatores de risco para doenças cardiovasculares e diabetes geralmente ligados à resistência à insulina, à obesidade e à obesidade central. Consonante com a patogênese inflamatória bem-estabelecida da doença aterosclerótica, a síndrome metabólica está agora sendo pesquisada em relação à sua natureza inflamatória. OBJETIVO: Apresentamos dados transversais demonstrando que marcadores de inflamação se correlacionam com componentes da síndrome metabólica, e dados prospectivos do Estudo ARIC indicando que marcadores de inflamação e de disfunção endotelial predizem o desenvolvimento de diabetes mellitus e ganho de peso em adultos. Apresentamos evidências biológicas que sugerem que a ativação crônica do sistema imune inato pode ser a base da síndrome metabólica, caracterizando o solo comum para a causalidade do diabetes mellitus tipo 2 e da doença cardiovascular. CONCLUSÕES: O melhor entendimento do papel do sistema imune inato nessas doenças poderá levar a avanços importantes na predição e manejo do diabetes e da doença cardiovascular.
Downloads
Referências
Stern MP. Diabetes and cardiovascular disease. The “common soil” hypothesis. Diabetes 1995;44(4):369-74.
Reaven GM. Banting Lecture 1988: role of insulin resistance in hu- man disease. Diabetes 1988;37:1595-607.
DeFronzo RA, Ferranini E. Insulin Resistance: a multifaceted syn- drome responsible for NIDDM, obesity, hypertension, dyslipidemia, and other atherosclerotic cardiovascular disease. Diabetes Care 1991;14:173-94.
Alberti KGMM, Zimmet PZ, for the WHO Consultation. Defini- tion, diagnosis and classification of diabetes mellitus and its compli- cations. Part 1: Diagnosis and classification of diabetes mellitus, pro- visional report of a WHO consultation. Diabet Med 1998;15:539- 53.
Schmidt MI, Watson RL, Duncan BB, Metcalf P, Brancati FL, Sharrett AR, Davis CE, Heiss G, for the ARIC Investigators. Clustering of dyslipidemia, hyperuricemia, diabetes, and hypertension and its as- sociation with fasting insulin and central and overall obesity in a general population. Metabolism 1996;45(6):699-706.
Zimmet PZ, Collins VR, Dowse GK, et al. Is hyperinsulinemia a central characteristic of a chronic cardiovascular risk factor clustering syndrome? Mixed findings in Asian Indian, Creole and Chinese Mauritians. Mauritius Non-communicable Disease Study Group. Diabet Med 1994;11(4):388-96.
Schmidt MI, Duncan BB, Watson RL, Sharrett AR, Brancati FL, Heiss G. A metabolic syndrome in whites and African-Americans: the Atherosclerosis Risk in Communities baseline study. Diabetes Care 1996;19(5):414-8.
Ross R. Atherosclerosis: an inflammatory disease. New Engl J Med 1999;340(2):115-26.
Lindberg G, Lundblad A, Gullberg B, Nilsson-Ehle P, Hanson BS. Serum total sialic acid and sialoprotein concentration in relation to coronary heart disease risk markers. Atherosclerosis 1993;103:123-9.
Lindberg G, Eklund GA, Bullberg B, Rastam L. Serum sialic acid concentration and cardiovascular mortality. BMJ 1991;302:143-6.
Ridker PM. Evaluating novel cardiovascular risk factors: Can we bet- ter predict heart attacks? Ann Intern Med 1999;130:933-7.
Saito I, Folsom AR, Brancati FL, Duncan BB, Chambless LE, McGovern PG. Nontraditional risk factors for coronary heart disease incidence among persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. Ann Intern Med 2000;133(2):81-91.
Duncan BB, Schmidt MI, Offenbacher S, Wu KK, Savage PJ, Heiss G. Factor VIII and other hemostasis variables are related to incident diabetes in adults: the Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care 1999;22(5):767-72.
Schmidt MI, Duncan BB, Sharrett AR, et al. Markers of inflam- mation and prediction of diabetes mellitus in adults (Atherosclero- sis Risk in Communities study): a cohort study. Lancet 1999;353:1649-52.
Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a dis- ease of the innate immune system: association of acute-phase reac- tants and interleukin-6 with metabolic syndrome X. Diabetologia 1997;40:1286-92.
Yudkin JS, Stehouwer CDA, Emeis JJ, Coppack SW. C-reactive pro- tein in healthy subjects: association with obesity, insulin resistance, and endothelial dysfunction. Arterioscler Thromb Vasc Biol 1999;19:972-8.
FestaA, D’Agostino RB, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resist- ance syndrome. The Insulin ResistanceAtherosclerosisStudy (IRAS). Circulation 2000;201:42-7.
Morange PE,Alessi MC, Verdier M, Casanova D, Magalon G, Juhan- Vague I. PAI-1 produced ex vivo by human adipose tissue is relevant to PAI-1 blood level.Arterioscler Thromb VascBiol 1999;19(5):1361- 5.
Funahashi T, Nakamura T, Shimomura K, Maeda K, Kuriyama H, Takahashi M, AritaY, Kihara S, MatsuzawaY. Role ofadipocytokines on the pathogenesis of atherosclerosis in visceral obesity. Intern Med 1999;38:202-6.
Mohamed-AliV, GoodrickS, Rawesh A, Katz DR, Miles JM,Yudkin JS, Klein S, Coppack SW. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 1997;82(12):4196-200.
Duncan BB, Schmidt MI, Chambless LE, Folsom AR, Carpenter M, Heiss G, for the ARIC Investigators. Fibrinogen, other putative markers of inflammation and weight gain in middle-aged adults. The ARIC Study. Obesity Res 2000;8(4):279-86.
Pickup JC, Crook MA. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 1998;41(10):1241-8.
Fearon DT, Locksley RM. The instructive role of innate immunity in the acquired immune response. Science 1996;272:50-3.
Memon RA, Feingold KR, Grunfeld C. Cytokines and intermedi- ary metabolism. In: Remick DG, Friedland JS, editors. Cytokines in health and disease. 2nd edition. NewYork: Marcel Dekker; 1997:381- 99.
Kushner I, Mackiewicz A. The acute phase response: an overview. In: Mackiewicz A, Kushner I, Baumann H, editors. Acute Phase Proteins: Molecular Biology, Biochemistry, and ClinicalApplications. Boca Raton: CRC Press; 1993:4-19.
Bjorntorp P, Rosmond R. The metabolic syndrome: a neuroendo- crine disorder? Br J Nutr 2000;83(Suppl 1):S49-S57.
Bjorntorp P, Rosmond R. Neuroendocrine abnormalities in visceral obesity. Int J Obes Relat Metab Disord 2000;24(Suppl 2):S80-S85.
Reichlin S. Neuroendocrinology. In: Reichlin S, Wilson JD, Foster DW, Kronenberg HM, Larsen PR, editors. Williams Text- book of Endocrinology. 9th ed. Philadelphia: WB Saunders Co.; 1998:165-248.
Hotamisligil GS. Mechanisms of TNF-a induced insulin resistance. Exp Clin Endocrinol Diabetes 1999;107:119-25.
Khovidhunkit W, Memon RA, Feingold KR, Grunfeld C. Infection and inflammation-induced proatherogenic changes of lipoproteins. J Infect Dis 2000;181(Suppl 3):S462-S472.
Campos SP, Baumann H. Insulin is a prominent modulator of the cytokine-stimulated expression of acute-phase plasma protein genes. Molec Cell Biol 1992;12(4):1789-992.
Melidonis A, Stefanidis A, Tournis S, et al. The role of strict meta- bolic control by insulin infusion on fibrinolytic profile during an acute coronary event in diabetic patients. Clin Cardiol 2000;23(3):160-4.
Ceriello A. Hyperglycemia: the bridge between non-enzymatic glycation and oxidative stress in the pathogenesis of diabetic complications. Diabetes Nutr Metab 1999;12(1):42-6.
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
